Q4 2024 Integra Lifesciences Holdings Corp Earnings Call Transcript
Key Points
- Integra Lifesciences Holdings Corp (IART) reported a total revenue of $443 million for the fourth quarter, representing a year-over-year growth of 11.5%, which was within their guidance range.
- The company successfully cleared many of the third-quarter shipping holds, contributing to a $62 million sequential revenue increase over the third quarter.
- Fourth-quarter adjusted EPS was $0.97, exceeding the guidance range, indicating strong financial performance.
- The company is making significant progress in its Compliance Master Plan, which aims to improve manufacturing processes and global quality management systems.
- Integra Lifesciences Holdings Corp (IART) is advancing its global expansion strategy, with increased market presence in Brazil, India, Korea, and China, and is building in-China-for-China manufacturing capabilities.
- The company faces operational challenges, particularly in quality, manufacturing, and supply chain improvements, which remain a top priority.
- First-quarter 2025 revenues are forecasted to be between $375 million and $385 million, with organic growth expected to be negative, ranging from -6.2% to -3.5%.
- The company has identified $18 million to $20 million in quality-related shipping holds impacting the first quarter of 2025.
- Integra Skin production is expected to face constraints in the first quarter of 2025 due to scheduled maintenance and lower-than-historical safety stock levels.
- The company anticipates a 70 basis point decrease in gross margin for 2025 due to investments in the Compliance Master Plan and potential supply disruptions.
Good day, and thank you for standing by. Welcome to the Integra LifeSciences' fourth-quarter 2024 financial results. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Chris Ward, Senior Director of Investor Relations. Please go ahead.
Good morning and thank you for joining the Integra LifeSciences' fourth-quarter 2024 earnings conference call. Joining me on the call this morning are Mojdeh Poul, President and Chief Executive Officer; and Lea Knight, Chief Financial Officer. This morning, we issued a press release announcing our fourth-quarter and full-year 2024 financial results.
The release and corresponding earnings presentation, which we will reference during the call, are available at integralife.com under Investors, Events and Presentations in the file named Fourth Quarter 2024 Earnings Call Presentation. Before we begin, I want to remind you that many of the statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
